Drug Profile
DRGT 19
Alternative Names: DRGT19Latest Information Update: 03 Sep 2020
Price :
$50
*
At a glance
- Originator Druggability Technologies
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pneumocystis pneumonia
Most Recent Events
- 01 Sep 2020 Druggability Technologies is now called Tavanta Therapeutics
- 27 Mar 2018 Discontinued - Preclinical for Pneumocystis pneumonia in Hungary (Druggability Technologies pipeline, March 2018)
- 15 May 2017 Preclinical trials in Pneumocystis pneumonia in Hungary (Druggability Technologies pipeline, May 2017)